MLH1 and neoplasm: Three patients were assessed for tumour mutation burden in the cohort, the two patients with low TMB (2Mut/Mb) had one and two actionable variants respectively including one DDR mutation (TP53 C238Y and PTEN I238T; EGFR amplification) compared with a patient with high TMB (107Mut/Mb) harbouring 9 actionable variants including 3 DDR mutations (CDKN2A Deletion, CDKN2B Deletion, IDH1 R132H, MLH1 Q301, NF1 Q236*, PIK3R1 N564D, PTEN G251D, TP53 R273C/H214L).